H.R. 1532 · 119th Congress (2025–2027)
Scientific EXPERT Act of 2025
This bill requires the Food and Drug Administration (FDA) to facilitate and participate in externally led, science-focused drug development meetings to discuss the development of treatments for rare diseases and conditions.
The FDA must enter into an arrangement with the Reagan-Udall Foundation for the FDA under which the foundation agrees to convene such meetings. Meetings must be held at least four times a year, and each meeting must focus on a different rare disease or condition.
The foundation must establish a permanent steering committee to review and recommend topics for each meeting. In evaluating potential topics, the committee must consider unmet therapeutic needs, patient population sizes for different diseases and conditions, and whether a disease or condition would benefit from clarity and alignment on drug development questions, among other factors.
In planning each meeting, the foundation must develop a list of medical experts, drug sponsors, scientific organizations, patient organizations, and other entities to be invited to participate. Representatives of the FDA’s review divisions must attend each meeting.
After each meeting, the foundation must make available a summary of the meeting noting areas of consensus, areas where additional clarification or information is needed, and next steps agreed upon with the FDA.
The bill also requires the FDA to indicate whether it incorporated any input from these meetings when approving a new drug or biologic.
Show official title
To amend the Federal Food, Drug, and Cosmetic Act to establish a process for externally led, science-focused drug development meetings, and for other purposes.
Referred to committee
Latest actionReferred to committee
This bill’s path
This is H.R. 1532’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
- Sponsor
- Rep. Doris O. Matsui (D-CA-7)
- Cosponsors
10 cosponsors
1 original · 9 later
3 R · 7 D
- Rep. Gus M. Bilirakis (R-FL-12)· Original · Feb 24, 2025
- Rep. Paul Tonko (D-NY-20)· Later · Jun 10, 2025
- Rep. Lloyd Doggett (D-TX-37)· Later · Aug 13, 2026
- Del. Eleanor Holmes Norton (D-DC)· Later · Aug 17, 2026
- Rep. Brian K. Fitzpatrick (R-PA-1)· Later · Aug 20, 2026
- Rep. Lloyd Smucker (R-PA-11)· Later · Sep 21, 2026
- Rep. Salud O. Carbajal (D-CA-24)· Later · Oct 22, 2026
- Rep. Maggie Goodlander (D-NH-2)· Later · Oct 22, 2026
- Rep. Shri Thanedar (D-MI-13)· Later · Oct 22, 2026
- Rep. Sarah McBride (D-DE)· Later · Nov 2, 2026
- Policy area
- Health
- Subjects
- Advisory bodies
- Congressional oversight
- Drug safety, medical device, and laboratory regulation
- Government information and archives
- Medical research
- Research administration and funding
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (3)
Scientific EXPERT Act of 2025
Display title, Short title · Introduced in House
Scientific External Process for Educated Review of Therapeutics Act of 2025
Short title · Introduced in House
To amend the Federal Food, Drug, and Cosmetic Act to establish a process for externally led, science-focused drug development meetings, and for other purposes.
Official title · Introduced in House